BioCentury
ARTICLE | Clinical News

Avastin bevacizumab: Final Phase II data

September 7, 2009 7:00 AM UTC

Final data from the open-label, pivotal Phase II BRAIN trial in 167 patients with recurrent GBM showed that 6-month PFS was observed in 42.6% of patients receiving Avastin monotherapy and in 50.3% of patients receiving Avastin plus irinotecan. The objective response rates for Avastin monotherapy and Avastin plus irinotecan were 28.2% and 37.8%, respectively, and median overall survival times were 9.2 months and 8.7 months, respectively. Avastin monotherapy and Avastin plus irinotecan were well tolerated. Data were published in the Journal of Clinical Oncology. The company reported an earlier analysis of the data in 2007 (see BioCentury, Dec. 3, 2007). ...